Pharmacogenetic approach for cancer treatment-tailored medicine in practice

Yoshinori Hasegawa, Yuichi Ando, Maki Ando, Naozumi Hashimoto, Kazuyoshi Imaizumi, Kaoru Shimokata

Research output: Chapter in Book/Report/Conference proceedingConference contribution

18 Citations (Scopus)


This article focuses on pharmacogenetic associations between genetic polymorphism of uridine diphosphate glucuronosyltransferase (UGT) 1A1 gene and irinotecan toxicity. Accumulating evidence provides support to the idea that determination of UGT1A1 polymorphisms before irinotecan treatment is clinically useful and important for predicting and avoiding related toxicities. On the basis of these backgrounds, the irinotecan label was updated in 2005 in the United States to provide pharmacogenetic information, and a dose reduction of irinotecan should be considered for patients known to be homozygous for the UGT1A1*28 allele when administered in combination with other agents or a single agent. The irinotecan/UGT1A1 issue and the development of molecular diagnostic testing are now to be translated into clinical practice.

Original languageEnglish
Title of host publicationIntegrated Molecular Medicine for Neuronal and Neoplastic Disorders
PublisherBlackwell Publishing Inc.
Number of pages10
ISBN (Print)1573316555, 9781573316552
Publication statusPublished - 11-2006
Externally publishedYes

Publication series

NameAnnals of the New York Academy of Sciences
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science


Dive into the research topics of 'Pharmacogenetic approach for cancer treatment-tailored medicine in practice'. Together they form a unique fingerprint.

Cite this